Virologic failure and HIV-1 drug resistance among antiretroviral therapy recipients in an urban resource-limited setting - the South African Virologic Evaluation (SAVE) study by El-Khatib, Ziad
 Department of Public Health Sciences  
Virologic failure and HIV-1 drug resistance among 
antiretroviral therapy recipients in an urban resource-
limited setting  
- the South African Virologic Evaluation (SAVE) study 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska Institutet 
offentligen försvaras Rockefeller Hall, Nobels väg 11 
 
Monday, 18 April 2011, time: 9.00 
 
av 
Ziad El-Khatib 
MSc  
 
Huvudhandledare:  
Anna Mia Ekström, MD, MPH, PhD  
Associate Professor  
Div. of Global Health (IHCAR); Karolinska Institutet, 
Stockholm, Sweden  
 
Bihandledare:  
David Katzenstein, MD  
Professor  
Div. of Infectious Diseases; Stanford University 
California, USA 
 
Lynn Morris, DPhil  
Professor 
AIDS Virus Research Unit, National Institute for 
Communicable Diseases (NICD)  
Johannesburg, South Africa 
 
Max Petzold, PhD 
Associate Professor 
Nordic School of Public Health (NHV) 
Gothenburg, Sweden 
Fakultetsopponent: 
Jean Nachega, MD, PhD, MPH, DTM&H 
Associate Scientist 
Dept. of International Health;  
Johns Hopkins Bloomberg School of Public 
Health Maryland, USA. 
And 
Extraordinary Professor 
Dept. of Medicine; Stellenbosch University 
Faculty of Health Sciences; 
Cape Town, South Africa 
 
Betygsnämnd: 
Jan Albert, MD  
Professor  
Dept. of Microbiology, Tumor and Cell Biology 
Karolinska Institutet  
Stockholm, Sweden 
 
Lars Lindquist, MD, PhD 
Professor 
Unit for Infectious Diseases 
Department of Medicine; Karolinska University 
Hospital; Huddinge, Sweden 
 
Åsa Kettis-Lindblad, MSc, PhD 
Associate Professor 
Department of Pharmacy, Uppsala Biomedical 
Center (BMC) 
Uppsala University, Uppsala, Sweden 
                Stockholm 2011 
Abstract 
In sub-Saharan Africa, more than four million HIV-infected people have been initiated on antiretroviral 
therapy (ART); most only have access to first line-treatment, and few ART clinics can provide second-line 
regimens to everyone in need due to the cost of equipment to detect virologic failure and the cost of 
alternative drugs. Hence, sustaining the usage of first-line regimens is crucial. More than 25% of ART 
recipients are residents of South Africa. The overall aim of this thesis was to study determinants of virologic 
failure and the development of drug resistance among ART recipients in South Africa. 
Article I: We assessed, longitudinally, risk factors for incomplete adherence in a cohort of HIV-infected 
women (n=154) initiating ART and examined the association between adherence to ART and virologic 
response. Seven per cent had a viral load (VL) >400 copies/ml at month 6 on ART. Incomplete adherence 
was associated with lower education (p=0.01) and lack of financial support from a partner (p=0.02) after 
adjustment for confounders. Only when adherence levels dropped below 80% was there a significant 
association with viremia in the group overall, although adherence <95% was associated with viremia among 
those exposed to single-dose nevirapine (sdNVP). 
Article II: Risk factors for virologic failure were assessed among long-term ART recipients in a cross-
sectional study in Soweto, among 998 patients receiving ART for >12 months. Fourteen per cent (n=139) of 
line-one ART recipients (n=883) had VL >400 copies/ml; 12% (102/882) on first-line vs 33% (37/115) on 
the second-line regimen were viremic. Two-thirds vs one-third on line-one vs line-two ART had drug-
resistance mutations (DRM). A history of poor adherence, concurrent HIV/TB treatment, being at a public 
clinic and not having a refrigerator at home were risk factors for virologic failure on treatment  
Article III: In a retrospective cohort study among 456 non-nucleoside reverse transcriptase inhibitor 
(NNRTI) recipients in Soweto, we assessed the association between coming late for drug refill visits, as one 
of the World Health Organization Early Warning Indicators (WHO-EWIs), and treatment failure. After a 
median of 15 months on ART, 19% (n=88) and 19% (n=87) had failed virologically (here defined as two 
repeated VL>50 copies/ml) and immunologically (as defined by WHO) respectively, and both types of 
failure were associated with coming late to drug refill. In the final multivariable model risk factors for 
virologic failure were incomplete adherence and previous exposure to sdNVP or any other antiretrovirals 
(ARVs). In Kaplan-Meier analysis the virologic failure rate by month 48 was 19% (adherent) vs 37% (non-
adherent). 
Article IV: Risk factors for HIV-1 DRM development and persistence of viremia were assessed among 43 
NNRTI-recipients with a VL >400 copies/ml after a minimum of 12 months on ART. Sequences were 
obtained from 38/43. Of those, 82% had 1-7 DRM. In bivariate analysis remote exposure to sdNVP or prior 
ARVs; higher CD4 cell counts; lower VL; and >6 months of virologic failure were significantly associated 
with number of DRM. Among 25 viremic patients that were continued on an NNRTI-containing regimen 
despite viremia, 12 (48%) re-suppressed after a median of 8 months, 6 with K103N and 3 with M184V. 
Thirteen (52%) had continued virologic failure, which was significantly associated with detectable VL >6 
months prior to study enrollment and number of DRM. 
Conclusion: Overall, about 1 in 10 failed virologically in these urban township settings in Johannesburg, 
South Africa. Most patients failing virologically after long-term ART had at least one DRM. Intensive 
adherence support appears particularly important among women with pre-exposure to ARVs and patients 
showing virologic failure. Adherence to drug refills works as an early warning indicator for both virologic 
and immunologic failure, and can be used in settings where measurement of viremia is unavailable. 
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